

1 **The Balancing Role of Distribution Speed against Varying Efficacy Levels of COVID-19**
2 **Vaccines under Variants**

3
4 Daniel Kim

5 *H. Milton Stewart School of Industrial and Systems Engineering, Georgia Institute of*
6 *Technology, Atlanta, GA 30332, email: dkim608@gatech.edu*

7
8 Pınar Keskinocak, Ph.D.

9 *H. Milton Stewart School of Industrial and Systems Engineering, Georgia Institute of*
10 *Technology, Atlanta, GA 30332, email: pinar@isye.gatech.edu*

11
12 Pelin Pekkün, Ph.D.

13 *Moore School of Business, University of South Carolina, Columbia, SC 29208,*
14 *email: pelin.pekgun@moore.sc.edu*

15
16 İnci Yıldırım, M.D., Ph.D.

17 *Department of Pediatrics, Section of Infectious Diseases and Global Health, Yale School of*
18 *Medicine and Yale Institute of Global Health, 1 Church Street, New Haven, CT 06510,*
19 *email: inci.yildirim@yale.edu*

20
21 **Corresponding Author:**

22 Pınar Keskinocak, Ph.D.

23 *H. Milton Stewart School of Industrial and Systems Engineering, Georgia Institute of*
24 *Technology, North Ave NW, Atlanta, GA 30332,*
25 *email: pinar@isye.gatech.edu, phone: [+1-404-894-2325](tel:+14048942325)*

26
27

28 **ABSTRACT**

29

30 Mutations in SARS-CoV-2 raised concerns about diminishing vaccine effectiveness against
31 COVID-19 caused by particular variants. Even with high initial efficacy, if a vaccine's efficacy
32 drops significantly against variants, or if it cannot be distributed quickly, it is uncertain whether
33 the vaccine can provide better health outcomes than other vaccines. Hence, we evaluated the
34 trade-offs between the *speed of distribution* vs. *efficacy against infection* of multiple vaccines
35 when variants emerge by utilizing a Susceptible-Infected-Recovered-Deceased (SIR-D) model
36 and assessing the level of *infection attack rate* (IAR). Our results show that speed is a key factor
37 to a successful immunization strategy to control the COVID-19 pandemic even when the
38 emerging variants may reduce the efficacy of a vaccine. Due to supply-chain challenges, the
39 accessibility and distribution of the vaccines have been hindered in many regions, especially in
40 low-income countries, while the second or third wave of the pandemic has occurred due to the
41 variants. Understanding the tradeoffs between speed and efficacy and distributing vaccines that
42 are available as quickly as possible are crucial to eradicate the pandemic before new variants
43 spread.

44

45 **KEYWORDS:** vaccination; disease modeling; COVID-19; vaccine efficacy; distribution speed

46

47 INTRODUCTION

48 Since the initial reports of a cluster of pneumonia cases of unidentified origin in Wuhan,
49 China, in December 2019, more than 265 million people around the world have been infected
50 with the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).¹ Despite the
51 development of effective vaccines in unprecedented speed, concerns have been raised on the
52 potential reduction in efficacy of these vaccines against the new SARS-CoV-2 variants due to
53 possible evasion from antibody recognition.^{2,3} In order to reach herd immunity, effective
54 implementation of a vaccine with sufficient efficacy against the circulating dominant variants is
55 essential. Subsequently, it becomes a trivial decision for policymakers and governments to favor
56 a vaccine with high efficacy for distribution. However, if the vaccine cannot be dispensed
57 quickly and/or if its efficacy drops significantly against the emerging variants compared to other
58 vaccines, the question of which vaccine should be favored is no longer trivial. Hence, the goal of
59 this study was to understand the tradeoffs between the speed of distribution vs. the change in the
60 efficacy levels of vaccines against infection before and after the emergence of variants, which we
61 referred to as "initial efficacy" and "final efficacy", respectively, hereafter.

62 The slow speed of procurement and dissemination of the SARS-CoV-2 vaccines has been a
63 continual challenge, particularly for low-income countries. Many low-income countries could
64 not even procure the small amount of vaccines since the high-income countries had reserved
65 large amounts.⁴ In addition, the vaccines, especially those with high efficacies, may encounter a
66 number of administrative and supply-chain related challenges in the low-income countries. For
67 instance, the mRNA vaccines for COVID-19 require ultra-cold storage and logistics, which are
68 often not readily available or easy to acquire.^{5,6} Due to such challenges, as of December 2021,

69 only 8% of people in low-income countries have received at least one dose of the vaccines, in
70 contrast to 65% of people in high-income countries.^{7,8}

71 The distributional challenges and delays lead to continuous infections, providing an
72 opportunity to the variants of the virus to emerge, which has raised concerns regarding reduced
73 efficacy of vaccines against emerging variants.⁹ As of December 2021, five concerning SARS-
74 CoV-2 variants have been identified: B.1.1.7, B.1.351, P.1, B.1.617.2, and B.1.1.529.¹⁰ These
75 have been classified as the variants of concern (VOC) because they have quickly become the
76 globally dominant forms.¹¹⁻¹⁴ The variant B.1.617.2 (delta), for instance, was classified as the
77 variant of concern by the World Health Organization (WHO) on May 11th, 2021 and quickly
78 became dominant in the United States in July 2021.^{10,15} These variants became more alarming as
79 multiple studies showed that the effectiveness of various vaccines decreased against the
80 variants.¹⁶⁻¹⁹

81 In this paper, we studied the trade-offs between vaccines' efficacy levels, which were subject
82 to reduction due to emerging variants and speed of vaccine distribution. We developed an
83 extended Susceptible-Infected-Recovered-Deceased (SIR-D) simulation model and assessed the
84 *infection attack rate* (IAR) under different times that the virus variants emerge. A number of
85 studies used the extended SIR-D model with different complications to study the impact of
86 public health interventions, including social distancing and vaccination.²⁰⁻²⁴ While some papers
87 examined the trade-offs between vaccine efficacy and distribution speed like ours,^{23,24} to the
88 best of our knowledge, this is the first paper to consider the impact of a change in vaccine
89 efficacy due to the emergence of variants. Throughout this paper, we referred to vaccine
90 distribution as the entire distribution process of a vaccine including delivery to the dispensation
91 sites and administration to the population. The results of this study were aimed to guide decision-

92 makers in vaccine ordering during a pandemic when there are multiple types of vaccines, facing
93 reduced efficacies as variants emerge.

94

95 METHODS

96 Vaccine Capacity

97 To compare different vaccine types, we categorized the level of the vaccine efficacy into
98 three ranges: “H” (High) if 90% or above, M (Moderate) if higher than 70% and lower than 90%,
99 and L (Low) if lower than 70%. We assumed that the final efficacy was always lower than the
100 initial efficacy. In our main simulation, we considered three initial efficacy levels ($H_i = 95\%$,
101 $M_i = 75\%$, and $L_i = 65\%$) and three final efficacy levels ($H_f = 90\%$, $M_f = 70\%$, and $L_f = 60\%$).
102 Consequently, we obtained six types of vaccines, defined by a particular initial and final efficacy,
103 as summarized in Table 1. These modeling choices were motivated by recent studies on vaccine
104 efficacy against variants.²⁵⁻²⁷

105

106

Table 1: Vaccine Efficacy

Vaccine Type	Initial Efficacy	Final Efficacy
$H_i H_f$	95%	90%
$H_i M_f$	95%	70%
$H_i L_f$	95%	60%
$M_i M_f$	75%	70%
$M_i L_f$	75%	60%
$L_i L_f$	65%	60%


107

108 We assumed in our simulations that all vaccines required a single dose and an individual who
109 received an *effective* vaccine became fully protected against the disease upon vaccination. In
110 each simulation, only a single type of vaccine was administered, and the daily vaccine
111 distribution capacity was kept constant at $\lambda \cdot K$, where K represents base capacity and λ is a

112 multiplier. We fixed the base capacity, K , at 500,000, motivated from the average number of
113 vaccine recipients in each day in the United States from December 14, 2020 to March 2, 2021,
114 and we set a range of 1.0 to 3.0 with increments of 0.2 for the capacity multiplier λ to represent
115 the speed of distribution in our simulations.²⁸

116 **Compartmental Epidemiological Model**

117 In our study, we utilized an extended SIR-D (Susceptible-Infectious-Recovered-Deceased)
118 compartmental model, which is a simplified mathematical model of infectious diseases. In this
119 model, individuals are moving among compartments, and transitions between compartments are
120 governed by ordinary differential equations given epidemiological and vaccine parameters. We
121 implemented seven compartments: *Susceptible* (S), *Vaccinated with immunity* (V), *Vaccinated-*
122 *susceptible* (S^v), *Symptomatic-infected* (I_S), *Asymptomatic-infected* (I_A), *Recovered* (R), and
123 *Deceased* (D). When *Susceptible* population received vaccines, they entered either the
124 *Vaccinated with immunity* (V) compartment if the vaccine was effective, or the *Vaccinated-*
125 *susceptible* (S^v) compartment, otherwise. Both *Susceptible* and *Vaccinated-susceptible*
126 populations transitioned to either the *Symptomatic-infected* (I_S) or *Asymptomatic-infected* (I_A)
127 compartment, once they made infectious contacts with the infected population. *Symptomatic-*
128 *infectious* population then moved to either the *Recovered* (R) or *Deceased* (D) compartment. We
129 assumed that asymptomatic patients always recovered in our model. The transition diagram of
130 the extended SIR-D model is depicted in Figure 1.



131

132 *Figure 1: Transition diagram of the extended SIR-D model, in which each move is dependent on*
 133 *the epidemiological and vaccine parameters; β_s symptomatic and asymptomatic*
 134 *transmission rates, respectively; β_a : symptomatic and asymptomatic recovery rates,*
 135 *respectively; μ : decrease rate of a symptomatic patient; $e \cdot v$: efficacy of the vaccine; $(1 - e) \cdot v$*
 136 *ratio of the daily vaccine capacity to the size of the unvaccinated susceptible population (i.e.,*
 137 *)*

138

139

140

141

142

143

144

145

146

147

148

149

We chose the epidemiological parameter values that govern the transitions in the compartment model based on the estimated SARS-CoV-2 characteristics in various studies. The infectious periods of a symptomatic patient and an asymptomatic patient were studied to be 14 days and 8 days, respectively.^{29,30} Therefore, we set the recovery rates of symptomatic patients () and asymptomatic patients () at 1/14 and 1/8, respectively. In addition, the CDC has developed COVID-19 Pandemic Planning Scenarios and provided parameter values to use in a mathematical model.³¹ Accordingly, we assumed that 60% of the susceptible population who made infectious contacts became symptomatic. In addition, we used 2.3 for the reproduction number (), which is often employed by epidemiologists to represent the infectivity of a disease. The symptomatic infection fatality rate (IFR-S) of COVID-19, the proportion of deaths among symptomatic infected individuals, was estimated as 1.3%.³² Given the reproduction number of

150 2.3 and the IFR-S, we set the symptomatic-transmission rate (β_s) to be 0.22031 and the death
151 rate (μ) to be 0.0032. We assumed that the asymptomatic-transmission rate (β_a) was 75% of the
152 symptomatic-transmission rate.³³ We used R-software to run the simulations with a population
153 size (N) of 330 million (approximate population of the United States). Since our main goal was
154 to analyze the trade-offs between distribution speed and vaccine's efficacy under variants, we
155 started the simulation only after when the vaccine became available and initialized it such that
156 around 28% of the population had already been infected. Thus, we set 2.90% of the population as
157 symptomatic-infected, 1.15% as asymptomatic-infected, 24.44% as recovered, and 0.14% as
158 deceased. These estimates were motivated by the *confirmed* cumulative cases and deaths as of
159 December 14, 2020, the first day of vaccine distribution in the United States.³⁴ However, we
160 multiplied the number of *confirmed* infections by six and increased the number of *confirmed*
161 deaths by 35% in line with the findings of Wu et al. (2020) and Noh and Danuser (2021), who
162 reported that the number of COVID-19 confirmed cumulative cases was underestimated, and
163 Kung et al. (2020), who showed the same for confirmed deaths.³⁵⁻³⁷ The initial values in other
164 compartments were estimated using the epidemiological parameters defined previously. All
165 parameters used in the extended SIR-D model are summarized in Table 2 and the non-linear
166 system of ordinary differential equations (ODEs) is as follows:

$$\frac{dS}{dt} = -\left(\min\left(1, \frac{\lambda \cdot K}{S \cdot N}\right) + \beta_s \left(1 - \min\left(1, \frac{\lambda \cdot K}{S \cdot N}\right)\right) I_S + \beta_A \left(1 - \min\left(1, \frac{\lambda \cdot K}{S \cdot N}\right)\right) I_A\right) S$$

$$\frac{dV}{dt} = e \cdot \min\left(1, \frac{\lambda \cdot K}{S \cdot N}\right) \cdot S$$

$$\frac{dS^v}{dt} = (1 - e) \cdot \min\left(1, \frac{\lambda \cdot K}{S \cdot N}\right) \cdot S - (\beta_s I_S + \beta_A I_A) \cdot S^v$$

$$\frac{dI_S}{dt} = p_S \cdot \left[\beta_s \left(1 - \min\left(1, \frac{\lambda \cdot K}{S \cdot N}\right)\right) I_S + \beta_A \left(1 - \min\left(1, \frac{\lambda \cdot K}{S \cdot N}\right)\right) I_A \right] \cdot S$$

$$+ p_S \cdot (\beta_S I_S + \beta_A I_A) \cdot S^v - \gamma_S I_S - \mu_S I_S$$

$$\frac{dI_A}{dt} = (1 - p_S) \cdot \left[\beta_S \left(1 - \min \left(1, \frac{\lambda \cdot K}{S \cdot N} \right) \right) I_S + \beta_A \left(1 - \min \left(1, \frac{\lambda \cdot K}{S \cdot N} \right) \right) I_A \right] \cdot S$$

$$+ (1 - p_S) \cdot (\beta_S I_S + \beta_A I_A) \cdot S^v - \gamma_A I_A$$

$$\frac{dR}{dt} = \gamma_S I_S + \gamma_A I_A$$

$$\frac{dD}{dt} = \mu_S I_S$$

Parameter	Description	Value
β_S, β_A	Transmission rate	0.22031, 0.16523
γ_S, γ_A	Recovery rate	1/14, 1/8
μ_S	Death rate	0.0032
N	Population size	330 million
p_S	Probability of developing symptoms	0.6
e	Vaccine efficacy	See Table 1
K	Base capacity	500,000
λ	Capacity multiplier	1.0 to 3.0 with increments of 0.2

167

Table 2: Parameters used in the extended SIR-D Model

168

169

We ran the simulation on a one-year planning horizon under different *mutation times* (i.e.,

170

the time at which the emerging variants becomes dominant and cause a decrease in a vaccine's

171

efficacy) within the range of day 5 to day 40 with a discrete step size of 5 days, and different

172

capacity multipliers (λ) within the range of 1.0 to 3.0 with a discrete step size of 0.2 to capture

173

the vaccine distribution speed. We evaluated the impact of each vaccine type using IAR as the

174

main health outcome.

175

176 **RESULTS**

177 We first ran our simulation without the presence of any vaccines, which gave an estimated
 178 IAR of approximately 81% and IFR-S of 2%. The daily infection peak (i.e., the highest
 179 percentage of the population who get newly infected on a single day) occurred on day 24, at
 180 which 1% of the population got newly infected.

181 Table 3 shows the estimated IAR under different capacity multipliers (λ) when the mutation
 182 times are day 5 and day 25. We report the full results with different mutation times in
 183 Supplemental Materials. When the mutation time is day 5, the level of IAR is between 60% and
 184 65% when the capacity multiplier is 3.0 (1.5M doses/day) and between 72% and 75% when the
 185 capacity multiplier is 1.0 (0.5M doses/day), depending on the selected vaccine type. When the
 186 mutation time is day 25, the level of IAR is smaller compared to when the mutation time is day 5,
 187 and the decrease in IAR due to the increase in capacity multiplier is larger.

188

Capacity Multiplier (λ)	Mutation Time = Day 5						Mutation Time = Day 25					
	H_iH_f	H_iM_f	H_iL_f	M_iM_f	M_iL_f	L_iL_f	H_iH_f	H_iM_f	H_iL_f	M_iM_f	M_iL_f	L_iL_f
3.0	60.19	63.02	64.63	63.55	65.17	65.45	59.81	60.98	61.64	63.13	63.86	65.01
2.8	61.16	63.92	65.48	64.43	65.99	66.25	60.80	61.96	62.63	64.02	64.74	65.83
2.6	62.18	64.86	66.36	65.34	66.84	67.09	61.84	63.00	63.65	64.95	65.66	66.69
2.4	63.25	65.84	67.27	66.28	67.72	67.95	62.92	64.07	64.72	65.92	66.61	67.58
2.2	64.38	66.86	68.22	67.27	68.64	68.85	64.06	65.20	65.83	66.93	67.60	68.50
2.0	65.55	67.91	69.20	68.29	69.58	69.78	65.26	66.37	66.98	67.98	68.62	69.45
1.8	66.79	69.01	70.22	69.36	70.56	70.74	66.52	67.59	68.18	69.07	69.68	70.44
1.6	68.08	70.16	71.27	70.47	71.58	71.74	67.83	68.86	69.42	70.20	70.78	71.47
1.4	69.44	71.35	72.36	71.62	72.63	72.77	69.22	70.19	70.71	71.38	71.92	72.53
1.2	70.87	72.58	73.48	72.82	73.72	73.84	70.67	71.57	72.05	72.61	73.10	73.63
1.0	72.37	73.86	74.65	74.06	74.85	74.95	72.20	73.00	73.43	73.89	74.32	74.77


189 Table 3: Infection attack rate (%) under different capacity multipliers and vaccine types when
 190 mutation time is day 5 and day 25

191

192 Figure 2 and Figure 3 present the contour plot and the two-dimensional plot of the IAR in
193 Table 3, respectively. Figure 2 shows that even vaccine- L_iL_f can achieve a lower IAR than
194 vaccine- H_iH_f if the capacity multiplier of vaccine- L_iL_f is high compared to that of vaccine- H_iH_f .
195 For instance, when the capacity multiplier of vaccine- H_iH_f is 1.0 and the mutation time is day 5,
196 72.3% of the population is infected. However, if the capacity multiplier of vaccine- L_iL_f is 1.48
197 (or higher), 72.2% (or less) of the population is infected. We present the minimum required
198 capacity multiplier of all vaccine types to achieve a lower IAR than vaccine- H_iH_f with the
199 capacity multiplier of 1.0 and 1.6 under different mutation times in Supplemental Materials.

200 Figure 4 compares the daily new infections from day 5 to day 50 with vaccine- H_iL_f vs.
201 vaccine- M_iM_f . In this figure, the mutation time is early (on day 5) and comes before the daily
202 infection peak, and thus, vaccine- M_iM_f results in a better IAR than vaccine- H_iL_f for all capacity
203 multipliers. Specifically, after the peak of daily new infections is reached for each vaccine, the
204 number of daily infections drops at a faster rate when vaccine- M_iM_f is administered. On the
205 other hand, when the mutation time comes after the daily infection peak (not shown in the figure),
206 vaccine- H_iL_f achieves a lower IAR than vaccine- M_iM_f for all capacity multipliers.

207




208

209

210 Figure 2: Graphical representation of infection attack rate under different capacity multipliers

211

with different vaccine types when mutation time is (a) day 5 and (b) day 25




212

213 Figure 3: Two-dimensional plot of infection attack rate under different capacity multipliers with

214 different vaccine types when mutation time is (a) day 5 and (b) day 25

215

216



217
218
219 Figure 4: Daily new infections from day 5 to day 50 with vaccine- and vaccine- when
220 the capacity multiplier (is 3 and the mutation time is day 5

221
222 **DISCUSSION**

223 In this study, we utilized an extended SIR-D model to simulate the trajectory of an infectious
224 disease under the intervention of different kinds of vaccines of which efficacies decrease against
225 the variants of the disease and different mutation times. We have demonstrated that the speed of
226 the vaccine distribution is a key factor to achieve low IAR levels, even though the vaccine may
227 have high efficacy both before and after the variants emerge.

228 Our study showed that a vaccine with low initial and final efficacy levels (vaccine-)
229 could achieve a lower IAR than a vaccine with high initial and final efficacy levels (vaccine-
230) if the former can be distributed more quickly than the latter, regardless of the mutation
231 time. In our simulation, when the mutation time was day 25 and the capacity multiplier of
232 vaccine- was 1.0 (0.5M doses/day), 72.2% of the population got infected. If the capacity

233 multiplier of vaccine- L_iL_f was 1.47 (0.73M doses/day or higher), 72.1% (or less) of the
234 population was infected (Table 3). Even for vaccines with the same initial efficacy, such as
235 vaccine- H_iH_f and vaccine- H_iL_f , this result remained robust—vaccine- H_iL_f with a capacity
236 multiplier of 1.18 (0.59M doses/day) or higher achieved a lower IAR than vaccine- H_iH_f with a
237 capacity multiplier of 1.0 (0.5M doses/day). Since the start of the COVID-19 vaccination process,
238 the speed of the vaccine distribution has been slow due to numerous reasons, including limited
239 and uncertain vaccine supply and various logistics and storage challenges. Despite the continuing
240 effort of increasing production capacities, vaccine manufacturers, especially those who produce
241 mRNA vaccines with new technology, have been struggling to secure sufficient supply of
242 vaccine ingredients, storage containers, and more, due to the demand from billions of people
243 around the world.³⁸ In addition, mRNA vaccines need to be stored in ultra-cold freezers under
244 specific expiration dates, although many communities, especially in the low-income countries,
245 lack or cannot afford such infrastructure, leading to a limited number of administration sites.
246 Besides the mRNA vaccines, numerous vaccines that require the same level of the resources that
247 the seasonal flu vaccine consumes have been developed and administered throughout the world.
248 These vaccines may prevent vaccine wastage, enable efficient production and distribution using
249 the existing vaccine supply chain, and facilitate a faster rate of vaccination.³⁹ Hence, despite
250 having lower efficacy than mRNA vaccines, those vaccines that have the potential for faster
251 distribution may be more beneficial.

252 Increasing the doses distributed per day, i.e., the capacity multiplier (λ), of any vaccine type
253 is always beneficial as it reduces the size of the susceptible population and can, eventually,
254 achieve herd immunity. Our study showed that the level of IAR always decreased when the
255 capacity multiplier was higher, with the largest impact observed for vaccine- H_iH_f . In particular,

256 when we compared the impact of changing the capacity multiplier from 1.0 to 3.0 for vaccine-
257 H_iH_f , vaccine- M_iM_f , and vaccine- L_iL_f , IAR changed from 72.20% to 59.81% for H_iH_f , from
258 73.89% to 63.13% for M_iM_f , and from 74.77% to 65.01% for L_iL_f , when the difference between
259 the initial and final efficacy was 5% for all the vaccine types and the mutation time was day 25.
260 In addition, if vaccine- H_iH_f could be distributed at a faster rate, the minimum required capacity
261 multiplier (λ) of vaccine- L_iL_f to achieve a lower IAR than vaccine- H_iH_f was even larger. For
262 example, when the mutation time was day 25, the capacity multiplier of vaccine- L_iL_f needed to
263 be at least 1.47 to achieve a lower IAR than vaccine- H_iH_f with the capacity multiplier of 1.0. On
264 the other hand, when the vaccine- H_iH_f 's capacity multiplier was 1.6, the capacity multiplier of
265 vaccine- L_iL_f needed to be at least 2.35. Thus, even though the difference in the capacity
266 multiplier of vaccine- H_iH_f was only 0.60, that of vaccine- L_iL_f was 0.88. However, increasing
267 the capacity multiplier, i.e., the speed of distribution, for vaccine- H_iH_f , which represents mRNA
268 vaccines in our model, may be much more challenging than that for vaccine- L_iL_f , as described
269 above, including economic burden, complications in vaccination programs, and unsophisticated
270 infrastructure. In such cases, it may be more beneficial to allocate resources towards distributing
271 a lower efficacy vaccine at a faster rate as our study shows.

272 Forecasting the time when the peak infections occur and when the variants emerge is also
273 critical to choosing which type of vaccine to distribute for maximizing public health benefits. If
274 the mutation time comes after the daily infection peak, a vaccine with a higher initial efficacy
275 always achieves a lower IAR than a vaccine with lower initial efficacy. However, if the mutation
276 time comes before the daily infection peak, the final efficacy level determines which vaccine
277 type achieves a lower IAR under the same capacity multiplier. For example, when we compared
278 vaccine- H_iH_f and vaccine- M_iM_f with a capacity multiplier of 1.0 for each, the daily infection

279 peak occurred on day 22 for both vaccines. Then, the administration of vaccine- M_iM_f , which has
280 an initial efficacy of 75% and final efficacy of 70%, resulted in an IAR of 74.06%, whereas the
281 administration of vaccine- H_iL_f , which has an initial efficacy of 95% and final efficacy of 60%,
282 resulted in an IAR of 74.65% (Figure 4). This is because an effective vaccination program
283 achieves the highest reduction in the number of new infections *before* the daily infection peak.
284 Afterwards, even with a higher initial efficacy, a vaccine with a lower final efficacy cannot
285 reduce the size of the susceptible population as much as a vaccine with a lower initial efficacy
286 and a higher final efficacy. Active genomic surveillance that studies the evolution of the virus
287 is critical to identify a new variant and study its influence on the spread of the disease and the
288 vaccine efficacy.⁴⁰ However the genomic surveillance has not received as much attention and the
289 coverage is still low.^{41,42} Our results demonstrated that an expedited detection of the variants and
290 their impact is vital to the choice of a vaccine to minimize the IAR.

291 **Limitation**

292 We acknowledge some limitations of this study. Our compartmental model provided insights
293 on the trade-offs between speed and efficacy against emerging variants without incorporating the
294 impact of other interventions. However, it can be extended to capture more realistic trajectory of
295 SARS-CoV-2, including more compartments or time-dependent epidemiological parameters.^{43,44}
296 In addition, we assumed that the population gains immunity as soon as they receive effective
297 vaccines and that every type of vaccine requires a single dose. In practice, the majority of the
298 authorized vaccines require two doses with three to four weeks apart application and it may take
299 several days to gain immunity after vaccination. Moreover, we did not consider any type of non-
300 pharmaceutical interventions. Depending on the number of people who conform to the

301 interventions, such as social distancing and mask mandates, the probability of infectious contacts
302 may vary over time.

303

304 **CONCLUSION**

305 Overall, our results suggested that the administration of a vaccine with high efficacy against
306 both the original strain and the variants may not always lead to a low number of cumulative
307 infections if it cannot be distributed as quickly as other vaccine types with lower efficacies.
308 Despite the vast efforts for worldwide vaccination, the vaccine distribution has been an ongoing
309 challenge due to production shortages, economic constraints, and the lack of advanced supply-
310 chain infrastructure, which is critical to distribute some of the high-efficacy vaccines. Due to
311 these challenges, the accessibility and distribution of the vaccines have been hindered especially
312 in many low- and middle-income countries.⁴⁵⁻⁴⁷ It is critical to distribute available vaccines as
313 quickly as possible and vaccinate more people to reach herd immunity before new variants
314 spread. Our study demonstrated that a vaccine with a relatively lower efficacy can achieve at
315 least as good health outcomes as their higher efficacy counterparts, as long as it can be
316 distributed more quickly. We hope that our study provides guidance to decision makers on the
317 tradeoffs between speed and efficacy, highlighting the critical role of speed of vaccination during
318 a pandemic as variants that decrease efficacy of vaccines emerge.

319

320 **REFERENCES**

321 1 World Health Organization. *WHO Coronavirus Disease (COVID-19) Dashboard*,
322 [<https://covid19.who.int>](https://covid19.who.int) (2020).

- 323 2 Karim, S. S. A. & Karim, Q. A. Omicron SARS-CoV-2 variant: a new chapter in the
324 COVID-19 pandemic. *The Lancet* (2021).
- 325 3 Sanders, R. W. & de Jong, M. D. Pandemic moves and countermoves: vaccines and viral
326 variants. *The Lancet* (2021).
- 327 4 Choi, E. M. COVID-19 vaccines for low- and middle-income countries. *Trans R Soc
328 Trop Med Hyg* **115**, 447-456, doi:10.1093/trstmh/trab045 (2021).
- 329 5 Tregoning, J. S., Flight, K. E., Higham, S. L., Wang, Z. & Pierce, B. F. Progress of the
330 COVID-19 vaccine effort: viruses, vaccines and variants versus efficacy, effectiveness
331 and escape. *Nature Reviews Immunology*, 1-11 (2021).
- 332 6 Fischer, W. A., II, M. G., Bhagwanjee, S. & Sevransky, J. Global burden of influenza:
333 contributions from resource limited and low-income settings. *Global heart* **9**, 325 (2014).
- 334 7 Hannah Ritchie *et al.* (Our World in Data, 2020).
- 335 8 Ramachandran, R., Ross, J. S. & Miller, J. E. Access to COVID-19 Vaccines in High-,
336 Middle-, and Low-Income Countries Hosting Clinical Trials. *JAMA Network Open* **4**,
337 e2134233-e2134233 (2021).
- 338 9 Knight, K. & Radhakrishnan, A. *Omicron Latest Reminder That Global Vaccine Equity
339 Is Critical*, (2021).
- 340 10 World Health Organization. *Tracking SARS-CoV-2 variants*,
341 [<https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/>](https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/) (2021).
- 342 11 Lauring, A. S. & Hodcroft, E. B. Genetic Variants of SARS-CoV-2—What Do They
343 Mean? *JAMA* (2021).

- 344 12 Smith-Schoenwalder, C. *CDC: Coronavirus Variant First Found in U.K. Now Dominant*
345 *Strain in U.S.*, <[https://www.usnews.com/news/health-news/articles/2021-04-07/cdc-](https://www.usnews.com/news/health-news/articles/2021-04-07/cdc-coronavirus-variant-first-found-in-uk-now-dominant-strain-in-us)
346 [coronavirus-variant-first-found-in-uk-now-dominant-strain-in-us](https://www.usnews.com/news/health-news/articles/2021-04-07/cdc-coronavirus-variant-first-found-in-uk-now-dominant-strain-in-us)> (2021).
- 347 13 Glatter, R. *P.1 Variant, Dominant Strain in Brazil, Reported in New York*,
348 <[https://www.forbes.com/sites/robertglatter/2021/03/21/p1-variant-dominant-strain-in-](https://www.forbes.com/sites/robertglatter/2021/03/21/p1-variant-dominant-strain-in-brazil-reported-in-new-york/?sh=449db2971883)
349 [brazil-reported-in-new-york/?sh=449db2971883](https://www.forbes.com/sites/robertglatter/2021/03/21/p1-variant-dominant-strain-in-brazil-reported-in-new-york/?sh=449db2971883)> (2021).
- 350 14 Adam, D. *What scientists know about new, fast-spreading coronavirus variants*,
351 <<https://doi.org/10.1038/d41586-021-01390-4>> (2021).
- 352 15 Centers for Disease Control and Prevention. *Variant Proportions*,
353 <<https://covid.cdc.gov/covid-data-tracker/#variant-proportions>> (2021).
- 354 16 Lopez Bernal, J. *et al.* Effectiveness of Covid-19 vaccines against the B. 1.617. 2 (Delta)
355 variant. *N Engl J Med*, 585-594 (2021).
- 356 17 Abu-Raddad, L. J., Chemaitelly, H. & Butt, A. A. Effectiveness of the BNT162b2 Covid-
357 19 Vaccine against the B.1.1.7 and B.1.351 Variants. *New England Journal of Medicine*
358 **385**, 187-189, doi:10.1056/NEJMc2104974 (2021).
- 359 18 Liu, C. *et al.* Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and
360 convalescent serum. *Cell*, doi:<https://doi.org/10.1016/j.cell.2021.06.020> (2021).
- 361 19 Wang, P. *et al.* Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7.
362 *Nature* **593**, 130-135, doi:10.1038/s41586-021-03398-2 (2021).
- 363 20 Grimm, V., Mengel, F. & Schmidt, M. Extensions of the SEIR model for the analysis of
364 tailored social distancing and tracing approaches to cope with COVID-19. *Scientific*
365 *Reports* **11**, 1-16 (2021).

- 366 21 Rădulescu, A., Williams, C. & Cavanagh, K. Management strategies in a SEIR-type
367 model of COVID 19 community spread. *Scientific reports* **10**, 1-16 (2020).
- 368 22 Usherwood, T., LaJoie, Z. & Srivastava, V. A model and predictions for COVID-19
369 considering population behavior and vaccination. *Scientific Reports* **11**, 1-11 (2021).
- 370 23 Paltiel, A. D., Schwartz, J. L., Zheng, A. & Walensky, R. P. Clinical Outcomes Of A
371 COVID-19 Vaccine: Implementation Over Efficacy: Study examines how definitions and
372 thresholds of vaccine efficacy, coupled with different levels of implementation
373 effectiveness and background epidemic severity, translate into outcomes. *Health Affairs*,
374 10.1377/hlthaff. 2020.02054 (2021).
- 375 24 Paltiel, A. D., Zheng, A. & Schwartz, J. L. Speed versus efficacy: quantifying potential
376 tradeoffs in COVID-19 vaccine deployment. *Annals of internal medicine* (2021).
- 377 25 Food and Drug Administration. *Fact Sheet for Healthcare Providers Administering*
378 *Vaccine (Vaccine Providers) Emergency Use Authorization (EUA) of the Janssen*
379 *COVID-19 Vaccine to Prevent Coronavirus Disease 2019 (COVID-19)*, (2021).
- 380 26 Pfizer. *Pfizer and BioNTech Confirm High Efficacy and No Serious Safety Concerns*
381 *Through Up to Six Months Following Second Dose in Updated Topline Analysis of*
382 *Landmark COVID-19 Vaccine Study*, <[https://www.pfizer.com/news/press-release/press-](https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-confirm-high-efficacy-and-no-serious)
383 [release-detail/pfizer-and-biontech-confirm-high-efficacy-and-no-serious](https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-confirm-high-efficacy-and-no-serious)> (2021).
- 384 27 Nanduri, S. *et al.* Effectiveness of Pfizer-BioNTech and Moderna vaccines in preventing
385 SARS-CoV-2 infection among nursing home residents before and during widespread
386 circulation of the SARS-CoV-2 B. 1.617. 2 (Delta) variant—National Healthcare Safety
387 Network, March 1–August 1, 2021. *Morbidity and Mortality Weekly Report* **70**, 1163
388 (2021).

- 389 28 Centers for Disease Control and Prevention. *COVID-19 Vaccinations in the United States*,
390 [<https://covid.cdc.gov/covid-data-tracker/#vaccinations>](https://covid.cdc.gov/covid-data-tracker/#vaccinations) (2020).
- 391 29 You, C. *et al.* Estimation of the time-varying reproduction number of COVID-19
392 outbreak in China. *International Journal of Hygiene and Environmental Health* **228**,
393 113555 (2020).
- 394 30 Byrne, A. W. *et al.* Inferred duration of infectious period of SARS-CoV-2: rapid scoping
395 review and analysis of available evidence for asymptomatic and symptomatic COVID-19
396 cases. *BMJ open* **10**, e039856 (2020).
- 397 31 Centers for Disease Control and Prevention. *COVID-19 Pandemic Planning Scenarios*,
398 [<https://www.cdc.gov/coronavirus/2019-ncov/hcp/planning-scenarios.html>](https://www.cdc.gov/coronavirus/2019-ncov/hcp/planning-scenarios.html) (2020).
- 399 32 Basu, A. Estimating The Infection Fatality Rate Among Symptomatic COVID-19 Cases
400 In The United States: Study estimates the COVID-19 infection fatality rate at the US
401 county level. *Health Affairs* **39**, 1229-1236 (2020).
- 402 33 Oran, D. P. & Topol, E. J. Prevalence of asymptomatic SARS-CoV-2 infection: a
403 narrative review. *Annals of internal medicine* **173**, 362-367 (2020).
- 404 34 Centers for Disease Control and Prevention. *COVID Data Tracker*,
405 [<https://covid.cdc.gov/covid-data-tracker/#datatracker-home>](https://covid.cdc.gov/covid-data-tracker/#datatracker-home) (2020).
- 406 35 Kung, S. *et al.* Underestimation of COVID-19 mortality during the pandemic. *ERJ open*
407 *research* **7** (2021).
- 408 36 Wu, S. L. *et al.* Substantial underestimation of SARS-CoV-2 infection in the United
409 States. *Nature communications* **11**, 1-10 (2020).
- 410 37 Noh, J. & Danuser, G. Estimation of the fraction of COVID-19 infected people in US
411 states and countries worldwide. *PloS one* **16**, e0246772 (2021).

- 412 38 Bushwick, S. *Why COVID Vaccines Are Taking So Long to Reach You*,
413 [https://www.scientificamerican.com/article/why-covid-vaccines-are-taking-so-long-to-](https://www.scientificamerican.com/article/why-covid-vaccines-are-taking-so-long-to-reach-you/)
414 [reach-you/](https://www.scientificamerican.com/article/why-covid-vaccines-are-taking-so-long-to-reach-you/)> (2021).
- 415 39 Johnson & Johnson. *Johnson & Johnson COVID-19 Vaccine Authorized by U.S. FDA for*
416 *Emergency Use - First Single-Shot Vaccine in Fight Against Global Pandemic*,
417 [https://www.jnj.com/johnson-johnson-covid-19-vaccine-authorized-by-u-s-fda-for-](https://www.jnj.com/johnson-johnson-covid-19-vaccine-authorized-by-u-s-fda-for-emergency-usefirst-single-shot-vaccine-in-fight-against-global-pandemic)
418 [emergency-usefirst-single-shot-vaccine-in-fight-against-global-pandemic](https://www.jnj.com/johnson-johnson-covid-19-vaccine-authorized-by-u-s-fda-for-emergency-usefirst-single-shot-vaccine-in-fight-against-global-pandemic)> (2021).
- 419 40 Robishaw, J. D. *et al.* Genomic surveillance to combat COVID-19: challenges and
420 opportunities. *The Lancet Microbe* (2021).
- 421 41 Cyranoski, D. *Alarming COVID variants show vital role of genomic surveillance*,
422 <https://www.nature.com/articles/d41586-021-00065-4>> (2021).
- 423 42 Anthes, E. *Why Didn't the U.S. Detect Omicron Cases Sooner?*,
424 [https://www.nytimes.com/2021/12/02/health/omicron-variant-genetic-](https://www.nytimes.com/2021/12/02/health/omicron-variant-genetic-surveillance.html)
425 [surveillance.html](https://www.nytimes.com/2021/12/02/health/omicron-variant-genetic-surveillance.html)> (2021).
- 426 43 Tindale, L. C. *et al.* Evidence for transmission of COVID-19 prior to symptom onset.
427 *Elife* **9**, e57149 (2020).
- 428 44 Cevik, M. *et al.* SARS-CoV-2, SARS-CoV, and MERS-CoV viral load dynamics,
429 duration of viral shedding, and infectiousness: a systematic review and meta-analysis.
430 *The Lancet Microbe* (2020).
- 431 45 Dyer, O. Covid-19: Many poor countries will see almost no vaccine next year, aid groups
432 warn. *BMJ: British Medical Journal (Online)* **371** (2020).
- 433 46 Andrew, S. *More than 130 countries don't have a single Covid-19 vaccine, while 10*
434 *countries have already dispersed 75% of all vaccines, the UN says*,

435 <[trnd/index.html](https://www.cnn.com/2021/02/18/world/united-nations-130-countries-no-vaccine-
436 (2021).

437 47 Acharya, K. P., Ghimire, T. R. & Subramanya, S. H. Access to and equitable distribution
438 of COVID-19 vaccine in low-income countries. *npj Vaccines* **6**, 54, doi:10.1038/s41541-
439 021-00323-6 (2021).

440

441 **Supplemental Materials**

442 Supplemental Table 1: Infection attack rate (%) under different capacity multipliers and mutation

443 times

Capacity multiplier (λ)	Mutation Time = Day 10						Mutation Time = Day 15					
	H _i H _f	H _i M _f	H _i L _f	M _i M _f	M _i L _f	L _i L _f	H _i H _f	H _i M _f	H _i L _f	M _i M _f	M _i L _f	L _i L _f
3.0	60.08	62.41	63.74	63.43	64.79	65.32	59.98	61.86	62.94	63.32	64.44	65.20
2.8	61.06	63.34	64.64	64.31	65.63	66.13	60.96	62.82	63.88	64.20	65.30	66.02
2.6	62.08	64.31	65.57	65.23	66.50	66.97	61.99	63.82	64.85	65.12	66.19	66.87
2.4	63.16	65.33	66.53	66.18	67.41	67.84	63.07	64.86	65.86	66.08	67.11	67.75
2.2	64.28	66.38	67.53	67.17	68.34	68.75	64.20	65.94	66.90	67.08	68.07	68.66
2.0	65.47	67.47	68.57	68.20	69.31	69.69	65.39	67.06	67.98	68.12	69.06	69.60
1.8	66.71	68.61	69.64	69.28	70.32	70.66	66.64	68.23	69.11	69.20	70.09	70.58
1.6	68.01	69.79	70.75	70.39	71.36	71.66	67.95	69.45	70.27	70.32	71.15	71.59
1.4	69.38	71.02	71.90	71.55	72.44	72.70	69.32	70.72	71.47	71.49	72.25	72.64
1.2	70.81	72.30	73.09	72.76	73.55	73.78	70.76	72.04	72.71	72.71	73.39	73.73
1.0	72.32	73.63	74.31	74.01	74.70	74.90	72.28	73.40	74.00	73.97	74.57	74.85

444

445

Capacity multiplier (λ)	Mutation Time = Day 20						Mutation Time = Day 30					
	H _i H _f	H _i M _f	H _i L _f	M _i M _f	M _i L _f	L _i L _f	H _i H _f	H _i M _f	H _i L _f	M _i M _f	M _i L _f	L _i L _f
3.0	59.89	61.39	62.24	63.22	64.13	65.10	59.75	60.63	61.14	63.06	63.62	64.92
2.8	60.87	62.36	63.21	64.11	65.00	65.92	60.74	61.63	62.14	63.95	64.52	65.75
2.6	61.91	63.38	64.21	65.03	65.91	66.77	61.78	62.67	63.18	64.88	65.44	66.61
2.4	62.99	64.44	65.25	66.00	66.85	67.66	62.86	63.76	64.26	65.86	66.40	67.51
2.2	64.13	65.54	66.33	67.00	67.82	68.57	64.01	64.90	65.39	66.87	67.40	68.43
2.0	65.32	66.69	67.45	68.04	68.83	69.52	65.21	66.08	66.57	67.92	68.44	69.39
1.8	66.57	67.89	68.62	69.13	69.87	70.51	66.47	67.32	67.80	69.01	69.51	70.39
1.6	67.89	69.14	69.82	70.26	70.96	71.53	67.79	68.62	69.07	70.15	70.63	71.42
1.4	69.27	70.44	71.07	71.44	72.08	72.58	69.18	69.96	70.39	71.34	71.78	72.48
1.2	70.72	71.79	72.37	72.66	73.24	73.68	70.63	71.37	71.76	72.57	72.98	73.59
1.0	72.24	73.20	73.70	73.93	74.44	74.81	72.16	72.83	73.19	73.85	74.22	74.73

446

Capacity multiplier (λ)	Mutation Time = Day 35						Mutation Time = Day 40					
	H _i H _f	H _i M _f	H _i L _f	M _i M _f	M _i L _f	L _i L _f	H _i H _f	H _i M _f	H _i L _f	M _i M _f	M _i L _f	L _i L _f
3.0	59.70	60.36	60.73	63.00	63.43	64.86	59.66	60.14	60.41	62.94	63.27	64.80
2.8	60.69	61.36	61.74	63.89	64.33	65.69	60.65	61.14	61.42	63.84	64.17	65.63
2.6	61.73	62.40	62.79	64.83	65.26	66.55	61.69	62.19	62.47	64.78	65.11	66.50
2.4	62.82	63.50	63.88	65.80	66.23	67.45	62.78	63.29	63.58	65.75	66.08	67.39
2.2	63.96	64.65	65.03	66.81	67.23	68.37	63.92	64.44	64.73	66.77	67.09	68.33
2.0	65.16	65.84	66.22	67.87	68.28	69.34	65.12	65.65	65.94	67.82	68.15	69.29
1.8	66.42	67.10	67.47	68.97	69.36	70.34	66.39	66.91	67.19	68.93	69.24	70.29
1.6	67.75	68.40	68.76	70.11	70.49	71.37	67.71	68.23	68.51	70.07	70.37	71.33
1.4	69.14	69.77	70.11	71.30	71.66	72.44	69.11	69.60	69.87	71.26	71.55	72.41
1.2	70.60	71.19	71.51	72.54	72.87	73.55	70.57	71.04	71.30	72.51	72.77	73.52
1.0	72.14	72.68	72.97	73.82	74.12	74.70	72.11	72.55	72.78	73.80	74.04	74.67

447

448

449 Supplemental Table 2: Minimum required capacity multiplier of each vaccine type under
450 different mutation times to achieve a lower IAR than vaccine- H_iH_f with the capacity multipliers
451 of 1.0 and 1.6

Mutation Time	H_iH_f : Capacity multiplier = 1.0					H_iH_f : Capacity multiplier = 1.6				
	H_iM_f	H_iL_f	M_iM_f	M_iL_f	L_iL_f	H_iM_f	H_iL_f	M_iM_f	M_iL_f	L_iL_f
5	1.24	1.40	1.28	1.45	1.48	1.97	2.23	2.04	2.33	2.37
10	1.2	1.33	1.28	1.43	1.48	1.91	2.11	2.04	2.27	2.37
15	1.17	1.27	1.28	1.4	1.47	1.85	2.01	2.04	2.23	2.36
20	1.14	1.22	1.27	1.38	1.47	1.81	1.93	2.03	2.19	2.35
25	1.12	1.18	1.27	1.36	1.47	1.77	1.86	2.03	2.16	2.35
30	1.1	1.15	1.27	1.34	1.46	1.73	1.81	2.03	2.13	2.34
35	1.08	1.12	1.27	1.33	1.46	1.7	1.76	2.03	2.11	2.34
40	1.06	1.09	1.27	1.31	1.46	1.68	1.72	2.03	2.09	2.34

452

453

454